MARKET

ZVRA

ZVRA

Zevra Therapeutics Inc
NASDAQ
5.06
-0.01
-0.20%
Closed 19:40 12/05 EST
OPEN
5.00
PREV CLOSE
5.07
HIGH
5.20
LOW
5.00
VOLUME
199.24K
TURNOVER
0
52 WEEK HIGH
6.44
52 WEEK LOW
3.890
MARKET CAP
209.92M
P/E (TTM)
-4.3722
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at ZVRA last week (1127-1201)?
Weekly Report · 2d ago
Weekly Report: what happened at ZVRA last week (1120-1124)?
Weekly Report · 11/27 09:17
Zevra Therapeutics Inc: Current report
Press release · 11/20 15:05
Weekly Report: what happened at ZVRA last week (1113-1117)?
Weekly Report · 11/20 09:17
Weekly Report: what happened at ZVRA last week (1106-1110)?
Weekly Report · 11/13 09:16
Zevra Therapeutics (NASDAQ:ZVRA investor five-year losses grow to 90% as the stock sheds US$6.8m this past week
Simply Wall St · 11/12 13:34
Zevra Therapeutics: Promising Growth Avenues and Potential Approvals Bolster Buy Rating
TipRanks · 11/08 19:15
Zevra Therapeutics’ Strategic Growth Potential and Undervaluation: A Buy Rating Justification
TipRanks · 11/08 12:37
More
About ZVRA
Zevra Therapeutics, Inc. is a rare disease company melding science, data, and patients need to create transformational therapies for diseases with limited or no treatment options. The Company has a diverse portfolio of products and product candidates, which includes a combination of both a clinical stage pipeline and commercial stage assets. Its pipeline includes arimoclomol, an orally delivered, investigational product candidate being developed for Niemann-Pick disease type C (NPC). KP1077 is the Company's lead clinical development product candidate which is being developed as a treatment for idiopathic hypersomnia (IH), a rare neurological sleep disorder, and narcolepsy. Its commercial product, AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder (ADHD), in patients aged six years and older containing its prodrug, serdexmethylphenidate (SDX), and d-methylphenidate (d-MPH). Its other commercial product is OLPRUVA. Its pipeline also includes EDSIVO and others.

Webull offers Zevra Therapeutics Inc stock information, including NASDAQ: ZVRA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ZVRA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ZVRA stock methods without spending real money on the virtual paper trading platform.